India formulations and innovative medicines drive growth in Q1FY27, with management reiterating FY27 guidance. Margins face near-term pressure from investments and the Organon acquisition.
Source link
Sun Pharma’s premium push cushions US generics pain in Q1, but valuations look full | Stock Market News
